Skip to main content

Closed

AKTS: Aktis Oncology, Inc. Stock Analysis | finqOS

Healthcare · Biotechnology

Loading chart data...

Current StateBalance holding

The verdict

Good business

Weak

Revenue growth+336.9% / yr

Operating margin-786.4%

ROIC-7.3%

Financially safe

Stretched

Debt / equity0.02×

Interest coverage0.0×

Current ratio19.49×

Aktis Oncology, Inc.

AKTSNASDAQ Global Select·USD·Closed

Aktis Oncology, Inc.

AKTSNASDAQ·USD·Closed

$22.07

−4.04%

$22.07

−$0.93 (4.04%)

52W Range

38thpctl

Volume

0.77×avg

Mkt Cap

1.18BUSD

P/E

-36.6TTM

Div Yield

–ann

52W Range

38thpctl

Volume

0.77×avg

Market Cap

1.18BUSD

P/E Ratio

-36.6TTM

Div Yield

-ann

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings

Overview Financials Peers Sentiment Analysis Transcripts Holders Company SEC Filings